### **Overview** NGL Fine Chem Ltd (formerly NGL Fine-Chem Limited) is a leading Indian manufacturer and exporter of **Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms**, with a dominant focus on the **veterinary pharmaceuticals sector**. Established in 1981 by Mr. Narayan Ganesh Lawande, the company has evolved over nearly five decades into **India’s foremost supplier of veterinary APIs and intermediates**, serving a global clientele across more than 50 countries. With over **92% of revenue derived from animal healthcare APIs**, NGL combines **backward integration, high in-house manufacturing (95%), and strong R&D capabilities** to maintain cost leadership while ensuring consistently high quality—evidenced by zero market rejections over the past **15 years**. --- ### **Core Business Segments** NGL operates under two primary verticals: - **Veterinary APIs (92% of revenue)** – Market-leading presence with leadership in key products such as **Homidium Chloride, Triclabendazole, Carprofen, Buparvaquone, Fluralaner**, and others. - **Human APIs (8% of revenue)** – Includes **Atovaquone (antimalarial)** and **Nitazoxanide (antidiarrheal/antipneumocystic)**, primarily targeting regulated global markets. Additionally, the company produces: - **4 advanced pharmaceutical intermediates** - **12 finished dosage forms** (for animal and human use) --- ### **Product Portfolio & Therapeutic Focus** As of Nov 2025: - **39 APIs**: 37 veterinary, 2 human - **4 intermediates** - **12 finished dosage forms** **Key Therapeutic Areas:** - Anthelmintics, Anti-inflammatories (NSAIDs) - Antiparasitics (ecto- and endo-), Antiprotozoals - Antibiotics, Phosphorus supplements - Companion animal health (strategic expansion) NGL has expanded its portfolio from 18 APIs in 2020 to 39 in 2025, with plans to launch **3–4 new products annually**, particularly focusing on **larger-market molecules** and those for **companion animals**. Notably, NGL is the **sole Indian manufacturer of fluralaner** (a key veterinary API), now off-patent, with active expansion underway in **Latin American markets** and preparations for U.S. and EU entry. It is also mastering the technically complex **afoxolaner** (NexGard), expected to go off-patent in 2028. --- ### **Market Position & Competitive Advantage** - **Leadership in Veterinary API Segment**: Holds **15%–over 50%** market share in key products, with **>50% share in top 5 molecules**. - **Supplies 5 of the Top 10 Global Animal Healthcare Companies**. - **Zero product rejections in 15 years**—a strong testament to quality and consistency. - **Backward-integrated, 95% in-house manufacturing** ensures cost competitiveness and supply chain control. - **Diversified global footprint**: Serves **~404 customers in over 51 countries**, across regulated (EU, U.S.) and unregulated (Africa, Asia, Middle East) markets. --- ### **Manufacturing & Infrastructure** - **Four state-of-the-art manufacturing facilities** located in **Tarapur and Navi Mumbai, Maharashtra**. - Combined API capacity: **600 tonnes/year** - Total area: **~10,800–11,000 sq. meters** - Reactor capacity: **194 m³ stainless steel, 102 m³ glass-lined, 12 m³ gas induction** - **75% of production from Zero Liquid Discharge (ZLD) facilities**, reflecting strong environmental compliance. - Plants are accredited under **WHO-GMP, cGMP, ISO**, and are compliant with global regulatory standards. --- ### **Strategic Expansion (CAPEX Program)** NGL is executing a **greenfield expansion at its Tarapur facility** (CAPEX: **₹160–170 crores**, 60:40 debt-equity mix), structured in two phases: | **Phase** | **Timeline** | **Focus** | |--------|------------|---------| | **Phase 1** | Commercialized by Q1 FY25–Q2 FY26 | Clean room, utilities, one API line | | **Phase 2** | On track for completion by Q3 FY26 | Additional production lines for EU/U.S. compliance | - The **new plant will serve regulated markets only** (U.S., EU, Latin America). - **Existing plants** will continue to serve the **Rest of World (RoW)**, including unregulated and lower-margin markets. - Outsourcing will continue for RoW at **~15%** to support volume demand during ramp-up. - **Meaningful sales from regulated geographies expected in FY27–FY28**, following customer validations and stability studies. --- ### **Regulatory Status & Market Entry Strategy** - **Europe**: - **3 CEPs (Certificates of Suitability) and 6 DMFs filed**. - FY25 sales: ₹30 crores; FY26 expected: ₹25–30 crores. - Onboarding slow due to regulatory timelines (now 1.5–2 years), but poised for growth. - **United States**: - U.S. FDA filing expected in **Oct–Dec 2025**, with approval targeted for **2027**, and meaningful sales from **FY28**. - Regulatory strategy leverages **strong R&D**, **pilot scale-up capabilities**, and alignment with **post-COVID ‘China+One’ sourcing shift**. --- ### **Global Reach & Exports** - **Exports account for ~70–73%** of total turnover. - Top markets include **Europe, Asia-Pacific, Latin America, Africa, and indirectly, the Middle East**. - Africa remains a key volume market but faces **intense pricing pressure from Chinese manufacturers**. - **Pakistan exports (₹15 crores in prior FY)** expected to drop to **zero** due to geopolitical issues. - **U.S. sales began in FY21** (non-FDA, EPA-regulated product), showing exponential growth (up 2919% in FY21). --- ### **Sales, Customers & Product Concentration** - **~404 global customers**, built on **long-term relationships**, **reliability**, **value pricing**, and **strong sales support**. - **Top 10 customers**: ~30% of sales → moderate concentration. - **Top 10 products**: **~69% of total sales** → **high product concentration**, though diversification efforts ongoing via R&D pipeline. - Customer decisions driven by **cost, quality, and reliability**—not country of origin. --- ### **R&D & Innovation** - **R&D Spend**: ₹6.47 crores in FY25. - **R&D Team**: ~25+ specialists focused on: - Complex multi-step organic synthesis - Chiral reduction, stereo-selective synthesis, high-pressure hydrogenation, hazardous reactions - Green chemistry, process optimization - **Pilot Plant**: 2,000 sq. ft. with reactors (200–400 L), bioreactor (2,000 L), glass-lined and gas induction reactors. - **Pipeline**: ~32 upcoming API products in development, reducing dependency on core products. --- ### **Strategic Vision** NGL Fine Chem is strategically **shifting from volume-driven, unregulated markets to high-margin, regulated geographies (U.S., EU, Latin America)**, to: - Improve profitability - Build a portfolio of approved products - Reduce exposure to volatile emerging markets **Key Growth Pillars**: 1. **Innovation & R&D** 2. **Market Expansion (Regulated Markets)** 3. **Operational Excellence (CAPEX, Process Reengineering)** 4. **Vertical Integration & Cost Leadership** The company sees the **‘China+One’ supply chain shift** as a **long-term tailwind** and is positioning itself as a **trusted, compliant, and agile alternative for global animal health innovators**. --- ### **Summary: Key Strengths** ✅ **Market Leadership in Veterinary APIs** ✅ **95% In-House Manufacturing + Backward Integration** ✅ **Zero Market Rejections in 15 Years – Benchmark Quality** ✅ **Expanding into High-Margin Regulated Markets (EU, U.S.)** ✅ **Strong R&D & Regulatory Pipeline** ✅ **Global Footprint & Diversified Client Base** ✅ **Strategic CAPEX to Drive Long-Term Growth & Margins**